Company Name, Ticker, Suppliers, else..

Worst Performing Stocks In Major Pharmaceutical Preparations Industry During The Previous 90 Days

1 Day

Week

Current Month of April

30 Days

Current Quarter Q2 of 2025

90 Days

Ytd

12 Months

Shares fell by -1.35% on average, in Major Pharmaceutical Preparations Industry during the previous 90 days.

Here are the Worst performing stocks in Major Pharmaceutical Preparations Industry.

VIRX

$0.0158

$-0.1531

-90.65%
Last 90 Days

VIRX

$0.0158

$-0.1531

-90.65%

Viracta Therapeutics Inc

Viracta Therapeutics Inc stock dropped -90.65% during the previous 90 days.

Viracta Therapeutics Inc is a biopharmaceutical company focused on developing targeted therapies for viral-associated cancers. The company aims to advance research, develop innovative treatments, and commercialize products to improve the lives of patients suffering from these types of cancers.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 0.625 mill.	$ - mill.	$ -43.289 mill.	40 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 0.625 mill.	$ - mill.	$ -43.289 mill.
Employees	Shares Outstanding	P/E
12	40 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

SYRS

$0.0269

$-0.1925

-87.74%
Last 90 Days

SYRS

$0.0269

$-0.1925

-87.74%

Syros Pharmaceuticals Inc

Syros Pharmaceuticals Inc shares went down -87.74% during the previous 90 days.

Syros Pharmaceuticals Inc operates based on a business model focused on developing targeted gene control therapies to treat various diseases. The company aims to leverage its gene control platform to identify and exploit unique gene regulatory networks to discover and develop novel therapeutics.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 1.058 mill.	$ - mill.	$ -97.815 mill.	39 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 1.058 mill.	$ - mill.	$ -97.815 mill.
Employees	Shares Outstanding	P/E
47	39 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

PLRX

$1.425

$-9.7850

-87.29%
Last 90 Days

PLRX

$1.425

$-9.7850

-87.29%

Pliant Therapeutics Inc

Pliant Therapeutics Inc stock dropped -87.29% during the previous 90 days.

Pliant Therapeutics Inc operates with a business model focused on developing novel therapeutics to address fibrotic diseases. The company conducts extensive research to identify and target specific molecular pathways involved in fibrosis, with the aim of developing effective treatments. Pliant Therapeutics collaborates with academic institutions and conducts preclinical and clinical studies to bring its products to market and improve the lives of patients suffering from fibrotic conditions.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 86.364 mill.	$ - mill.	$ -210.304 mill.	61 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 86.364 mill.	$ - mill.	$ -210.304 mill.
Employees	Shares Outstanding	P/E
26	61 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

PTPI

$0.0406

$-0.2595

-86.47%
Last 90 Days

PTPI

$0.0406

$-0.2595

-86.47%

Petros Pharmaceuticals inc

Petros Pharmaceuticals Inc stock went down -86.47% during the previous 90 days.

Petros Pharmaceuticals Inc is a pharmaceutical company that operates on a business model focused on the research, development, and commercialization of innovative drugs and therapeutics. They strive to bring new solutions to market by leveraging their expertise in various therapeutic areas, ultimately aiming to improve patient outcomes and well-being.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 0.399 mill.	$ 4.387 mill.	$ -23.037 mill.	10 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 0.399 mill.	$ 4.387 mill.	$ -23.037 mill.
Employees	Shares Outstanding	P/E
-	10 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

ATXI

$0.2651

$-1.5849

-85.67%
Last 90 Days

ATXI

$0.2651

$-1.5849

-85.67%

Avenue Therapeutics Inc

Avenue Therapeutics Inc shares went down -85.67% during the previous 90 days.

Avenue Therapeutics Inc is a pharmaceutical company that focuses on the development and commercialization of intravenous (IV) opioids for acute pain management. They aim to address the needs of the hospital-based market by providing innovative and effective IV pain medications. Through research, clinical trials, and partnerships with healthcare providers, Avenue Therapeutics Inc strives to improve healthcare outcomes for patients suffering from acute pain conditions.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 0.196 mill.	$ - mill.	$ -11.592 mill.	1 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 0.196 mill.	$ - mill.	$ -11.592 mill.
Employees	Shares Outstanding	P/E
11	1 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

BPTH

$0.165

$-0.6550

-79.88%
Last 90 Days

BPTH

$0.165

$-0.6550

-79.88%

Bio path Holdings inc

Bio Path Holdings Inc stock went down -79.88% during the previous 90 days.

Bio path Holdings Inc is a biotechnology company focused on developing RNA-based therapeutics for the treatment of diseases such as cancer. Their business model involves researching, developing, and commercializing these therapies to provide improved treatment options for patients.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 0.396 mill.	$ - mill.	$ -9.894 mill.	2 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 0.396 mill.	$ - mill.	$ -9.894 mill.
Employees	Shares Outstanding	P/E
9	2 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

PTN

$0.2304

$-0.8296

-78.26%
Last 90 Days

PTN

$0.2304

$-0.8296

-78.26%

Palatin Technologies Inc

Palatin Technologies Inc stock dropped -78.26% during the previous 90 days.

Palatin Technologies Inc has a business model focused on developing and commercializing innovative medicines in the field of reproductive healthcare and sexual dysfunction. The company*s revenue streams primarily come from partnerships, licensing agreements, and product sales.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 4.754 mill.	$ - mill.	$ -26.270 mill.	21 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 4.754 mill.	$ - mill.	$ -26.270 mill.
Employees	Shares Outstanding	P/E
11	21 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

PBM

$0.4546

$-1.3354

-74.60%
Last 90 Days

PBM

$0.4546

$-1.3354

-74.60%

Psyence Biomedical ltd

Psyence Biomedical Ltd stock declined -74.60% during the previous 90 days.

Pacific Booker Minerals Inc is engaged in the exploration and development of mineral properties, primarily focused on copper and gold projects in British Columbia, Canada. The company acquires mining rights and conducts extensive exploration to identify mineral deposits. Once a viable deposit is discovered, Pacific Booker Minerals Inc aims to develop and operate a mining operation to extract the minerals and sell them in the market.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 0.040 mill.	$ 0.001 mill.	$ -51.159 mill.	0 mill.	-	Y/Y -20.00 %

Market Cap.	Revenues TTM	Net Income TTM
$ 0.040 mill.	$ 0.001 mill.	$ -51.159 mill.
Employees	Shares Outstanding	P/E
65	0 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -20.00 %	MRQ Y/Y - %

CTXR

$0.9617

$-2.3383

-70.86%
Last 90 Days

CTXR

$0.9617

$-2.3383

-70.86%

Citius Pharmaceuticals Inc

Citius Pharmaceuticals Inc stock went down -70.86% during the previous 90 days.

Citius Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for a wide range of medical conditions. Their business model revolves around identifying unmet medical needs, conducting research and development to create novel drugs, and obtaining regulatory approvals for these drugs to bring them to market. They primarily aim to provide effective treatment options to patients and achieve commercial success through strategic partnerships and collaborations within the pharmaceutical industry.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 7.205 mill.	$ - mill.	$ -38.951 mill.	7 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 7.205 mill.	$ - mill.	$ -38.951 mill.
Employees	Shares Outstanding	P/E
51	7 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

QNRX

$5.8795

$-14.1125

-70.59%
Last 90 Days

QNRX

$5.8795

$-14.1125

-70.59%

Quoin Pharmaceuticals Ltd

Quoin Pharmaceuticals Ltd stock dropped -70.59% during the previous 90 days.

Quoin Pharmaceuticals Ltd operates on a direct-to-consumer (DTC) business model by developing and manufacturing pharmaceutical products for individual customers. The company focuses on creating specialized medicines tailored to meet the unique healthcare needs of patients. Quoin Pharmaceuticals aims to establish a close relationship with consumers, providing high-quality and personalized medications while bypassing traditional intermediaries in the pharmaceutical industry.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 27.589 mill.	$ -0.008 mill.	$ -8.962 mill.	5 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 27.589 mill.	$ -0.008 mill.	$ -8.962 mill.
Employees	Shares Outstanding	P/E
-	5 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

RDHL

$2.33

$-3.3067

-58.66%
Last 90 Days

RDHL

$2.33

$-3.3067

-58.66%

Redhill Biopharma Ltd

Redhill Biopharma Ltd shares went down -58.66% during the previous 90 days.

Redhill Biopharma Ltd is a specialty pharmaceutical company focused on improving patient care and developing innovative treatments. Their business model revolves around advancing the research and development of drug candidates in therapeutic areas with unmet medical needs. By seeking partnerships and leveraging their in-house expertise, they aim to bring these potential treatments to market for the benefit of patients worldwide.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 222.897 mill.	$ 6.530 mill.	$ 23.916 mill.	96 mill.	9.32	Y/Y -89.43 %

Market Cap.	Revenues TTM	Net Income TTM
$ 222.897 mill.	$ 6.530 mill.	$ 23.916 mill.
Employees	Shares Outstanding	P/E
24	96 mill.	9.32
Revenue Growth	Income Growth
MRQ Y/Y -89.43 %	MRQ Y/Y -66.63 %

PRAX

$32.77

$-37.7700

-53.54%
Last 90 Days

PRAX

$32.77

$-37.7700

-53.54%

Praxis Precision Medicines Inc

Praxis Precision Medicines Inc shares dropped -53.54% during the previous 90 days.

Praxis Precision Medicines Inc*s business model revolves around developing precision medicines for the treatment of various central nervous system (CNS) disorders.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 586.776 mill.	$ 8.553 mill.	$ -182.819 mill.	18 mill.	-	Y/Y 1,349.13 %

Market Cap.	Revenues TTM	Net Income TTM
$ 586.776 mill.	$ 8.553 mill.	$ -182.819 mill.
Employees	Shares Outstanding	P/E
82	18 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 1,349.13 %	MRQ Y/Y - %

PRPH

$0.2773

$-0.3180

-53.42%
Last 90 Days

PRPH

$0.2773

$-0.3180

-53.42%

Prophase Labs Inc

Prophase Labs Inc shares dropped -53.42% during the previous 90 days.

Prophase Labs Inc is a pharmaceutical company focused on developing and distributing consumer healthcare products.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 5.670 mill.	$ 12.258 mill.	$ -53.364 mill.	20 mill.	-	Y/Y 4.11 %

Market Cap.	Revenues TTM	Net Income TTM
$ 5.670 mill.	$ 12.258 mill.	$ -53.364 mill.
Employees	Shares Outstanding	P/E
24	20 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 4.11 %	MRQ Y/Y - %

PRQR

$1.145

$-1.2250

-51.69%
Last 90 Days

PRQR

$1.145

$-1.2250

-51.69%

Proqr Therapeutics N v

Proqr Therapeutics N V shares dropped -51.69% during the previous 90 days.

ProQR Therapeutics N.V. is a biopharmaceutical company that focuses on the development of RNA-based therapeutics to treat genetic diseases. They utilize their proprietary RNA technology platform to create innovative drugs that target the underlying cause of diseases.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ - mill.	$ - mill.	$ 0.000 mill.	- mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ - mill.	$ - mill.	$ 0.000 mill.
Employees	Shares Outstanding	P/E
48	- mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

XNCR

$9.43

$-9.8100

-50.99%
Last 90 Days

XNCR

$9.43

$-9.8100

-50.99%

Xencor Inc

Xencor Inc stock declined -50.99% during the previous 90 days.

Xencor Inc is a biotechnology company that primarily focuses on the development of therapeutic antibodies. Their business model revolves around utilizing their proprietary XmAb? technology to engineer antibodies with enhanced properties for the treatment of various diseases. They collaborate with pharmaceutical companies to develop and commercialize these antibody therapeutics, generating revenue through upfront payments, milestone payments, and royalties.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 612.734 mill.	$ 110.493 mill.	$ -236.540 mill.	65 mill.	-	Y/Y 3.58 %

Market Cap.	Revenues TTM	Net Income TTM
$ 612.734 mill.	$ 110.493 mill.	$ -236.540 mill.
Employees	Shares Outstanding	P/E
280	65 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 3.58 %	MRQ Y/Y - %

ZVSA

$0.7001

$-0.7199

-50.70%
Last 90 Days

ZVSA

$0.7001

$-0.7199

-50.70%

Zyversa Therapeutics Inc

Zyversa Therapeutics Inc shares dropped -50.70% during the previous 90 days.

Zyversa Therapeutics Inc*s business model revolves around developing innovative therapies and treatments for various medical conditions.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 0.777 mill.	$ - mill.	$ -9.413 mill.	1 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 0.777 mill.	$ - mill.	$ -9.413 mill.
Employees	Shares Outstanding	P/E
-	1 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

WVE

$5.755

$-5.2350

-47.63%
Last 90 Days

WVE

$5.755

$-5.2350

-47.63%

Wave Life Sciences Ltd

Wave Life Sciences Ltd stock dropped -47.63% during the previous 90 days.

Wave Life Sciences Ltd is a biotechnology company focused on developing and commercializing nucleic acid therapies for rare genetic diseases. Their business model revolves around utilizing their proprietary chemistry platform to design and create custom-built, targeted medicines that can potentially address a wide range of genetic disorders. They aim to bring these therapies through preclinical and clinical development stages and ultimately deliver innovative treatments to patients in need.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 797.544 mill.	$ 108.302 mill.	$ -97.008 mill.	139 mill.	-	Y/Y 188.23 %

Market Cap.	Revenues TTM	Net Income TTM
$ 797.544 mill.	$ 108.302 mill.	$ -97.008 mill.
Employees	Shares Outstanding	P/E
288	139 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 188.23 %	MRQ Y/Y - %

GRTX

$0.025

$-0.0200

-44.44%
Last 90 Days

GRTX

$0.025

$-0.0200

-44.44%

Galera Therapeutics Inc

Galera Therapeutics Inc shares dropped -44.44% during the previous 90 days.

Galera Therapeutics Inc is a pharmaceutical company that operates under an innovative business model focused on developing transformative therapies to treat cancer. They utilize a combination of in-house research, strategic partnerships, and scientific collaborations to discover, develop, and commercialize novel drug candidates. By leveraging their expertise and a patient-centric approach, Galera Therapeutics aims to revolutionize cancer treatment and improve patient outcomes.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 1.377 mill.	$ - mill.	$ -18.733 mill.	55 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 1.377 mill.	$ - mill.	$ -18.733 mill.
Employees	Shares Outstanding	P/E
50	55 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

ZNTL

$1.25

$-0.9900

-44.20%
Last 90 Days

ZNTL

$1.25

$-0.9900

-44.20%

Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc shares went down -44.20% during the previous 90 days.

Zentalis Pharmaceuticals Inc is a biopharmaceutical company that focuses on the discovery and development of small molecule therapies for the treatment of various types of cancer. Their business model revolves around leveraging their expertise in drug discovery, conducting clinical trials, and ultimately commercializing effective cancer treatments. By leveraging their innovative research and development capabilities, Zentalis aims to address unmet medical needs and improve the lives of cancer patients worldwide.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 88.969 mill.	$ 67.425 mill.	$ -165.867 mill.	71 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 88.969 mill.	$ 67.425 mill.	$ -165.867 mill.
Employees	Shares Outstanding	P/E
166	71 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

RCUS

$7.83

$-6.2000

-44.19%
Last 90 Days

RCUS

$7.83

$-6.2000

-44.19%

Arcus Biosciences Inc

Arcus Biosciences Inc stock went down -44.19% during the previous 90 days.

Arcus Biosciences Inc is a biotechnology company that focuses on developing immuno-oncology therapies. Their business model revolves around discovering and developing novel small molecule and antibody therapeutics to target various cancer indications. They aim to combine their extensive understanding of the immune system with innovative technology platforms to create effective treatments for patients with cancer.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 705.697 mill.	$ 258.000 mill.	$ -283.000 mill.	90 mill.	-	Y/Y -16.13 %

Market Cap.	Revenues TTM	Net Income TTM
$ 705.697 mill.	$ 258.000 mill.	$ -283.000 mill.
Employees	Shares Outstanding	P/E
21,164	90 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -16.13 %	MRQ Y/Y - %

PTIX

$0.25

$-0.1890

-43.05%
Last 90 Days

PTIX

$0.25

$-0.1890

-43.05%

Protagenic Therapeutics Inc new

Protagenic Therapeutics Inc New shares dropped -43.05% during the previous 90 days.

Protagenic Therapeutics Inc has developed a novel business model focused on the discovery and development of novel therapeutics targeting the PGRMC1 receptor, which plays a crucial role in various diseases. By leveraging their proprietary technology and partnerships, the company aims to advance the development of innovative drugs that can effectively treat a range of conditions influenced by the PGRMC1 receptor.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 1.222 mill.	$ - mill.	$ -5.525 mill.	5 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 1.222 mill.	$ - mill.	$ -5.525 mill.
Employees	Shares Outstanding	P/E
10	5 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

XBIO

$2.46

$-1.7800

-41.98%
Last 90 Days

XBIO

$2.46

$-1.7800

-41.98%

Xenetic Biosciences Inc

Xenetic Biosciences Inc shares dropped -41.98% during the previous 90 days.

Xenetic Biosciences Inc is a biopharmaceutical company that focuses on developing personalized therapeutics with the potential to improve patient outcomes. The company employs a business model centered around leveraging its proprietary drug development platform to partner with pharmaceutical companies and advance novel drug candidates through preclinical and clinical stages.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 3.791 mill.	$ 2.500 mill.	$ -3.960 mill.	2 mill.	-	Y/Y 6.16 %

Market Cap.	Revenues TTM	Net Income TTM
$ 3.791 mill.	$ 2.500 mill.	$ -3.960 mill.
Employees	Shares Outstanding	P/E
11	2 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 6.16 %	MRQ Y/Y - %

TRVN

$1.12

$-0.7400

-39.78%
Last 90 Days

TRVN

$1.12

$-0.7400

-39.78%

Trevena inc

Trevena Inc shares declined -39.78% during the previous 90 days.

Trevena Inc*s business model revolves around the development and commercialization of innovative medicines for the treatment of various medical conditions.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 0.955 mill.	$ - mill.	$ -34.036 mill.	1 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 0.955 mill.	$ - mill.	$ -34.036 mill.
Employees	Shares Outstanding	P/E
71	1 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

RCKT

$6.315

$-3.9950

-38.75%
Last 90 Days

RCKT

$6.315

$-3.9950

-38.75%

Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc stock went down -38.75% during the previous 90 days.

Rocket Pharmaceuticals Inc is a biotechnology company that focuses on the development and commercialization of gene therapies for rare and devastating diseases.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 598.528 mill.	$ - mill.	$ -258.746 mill.	95 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 598.528 mill.	$ - mill.	$ -258.746 mill.
Employees	Shares Outstanding	P/E
143	95 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

PYXS

$0.945

$-0.5550

-37.00%
Last 90 Days

PYXS

$0.945

$-0.5550

-37.00%

Pyxis Oncology Inc

Pyxis Oncology Inc stock dropped -37.00% during the previous 90 days.

Pyxis Oncology Inc is a biotechnology company focused on developing innovative cancer therapies. Their business model revolves around leveraging novel insights into the immune system to develop a pipeline of potential immunotherapies for cancer treatment. Pyxis Oncology aims to collaborate with strategic partners to advance their therapies through preclinical and clinical development, ultimately aiming to improve patient outcomes in the field of oncology.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 55.362 mill.	$ - mill.	$ -77.331 mill.	59 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 55.362 mill.	$ - mill.	$ -77.331 mill.
Employees	Shares Outstanding	P/E
10	59 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

QTTB

$2.07

$-1.2100

-36.89%
Last 90 Days

QTTB

$2.07

$-1.2100

-36.89%

Q32 Bio Inc

Q32 Bio Inc stock declined -36.89% during the previous 90 days.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 15.016 mill.	$ - mill.	$ -47.733 mill.	7 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 15.016 mill.	$ - mill.	$ -47.733 mill.
Employees	Shares Outstanding	P/E
42	7 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

XLO

$0.7351

$-0.4049

-35.52%
Last 90 Days

XLO

$0.7351

$-0.4049

-35.52%

Xilio Therapeutics Inc

Xilio Therapeutics Inc stock dropped -35.52% during the previous 90 days.

Xilio Therapeutics Inc is a biotechnology company focused on developing and commercializing novel immunotherapies to treat cancer.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 39.278 mill.	$ 6.344 mill.	$ -58.241 mill.	53 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 39.278 mill.	$ 6.344 mill.	$ -58.241 mill.
Employees	Shares Outstanding	P/E
64	53 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

PRTA

$9.26

$-4.5100

-32.75%
Last 90 Days

PRTA

$9.26

$-4.5100

-32.75%

Prothena Corporation Public Limited Company

Prothena Corporation Public Limited Company shares declined -32.75% during the previous 90 days.

Prothena Corporation is a biotechnology company that focuses on developing novel therapies for diseases related to protein misfolding and amyloidosis. Their business model includes leveraging their expertise in antibody and protein engineering to develop and commercialize drug candidates, collaborating with pharmaceutical partners to advance their therapeutic programs, and continuously conducting research and development to expand their pipeline of potential treatments. Their goal is to address unmet medical needs and provide innovative solutions for patients suffering from devastating diseases.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 498.939 mill.	$ 135.157 mill.	$ -122.310 mill.	54 mill.	-	Y/Y 571.84 %

Market Cap.	Revenues TTM	Net Income TTM
$ 498.939 mill.	$ 135.157 mill.	$ -122.310 mill.
Employees	Shares Outstanding	P/E
173	54 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 571.84 %	MRQ Y/Y - %

RAPT

$0.8076

$-0.3924

-32.70%
Last 90 Days

RAPT

$0.8076

$-0.3924

-32.70%

Rapt Therapeutics Inc

Rapt Therapeutics Inc shares declined -32.70% during the previous 90 days.

Rapt Therapeutics Inc operates based on a business model that focuses on developing and commercializing transformative oral small molecules, known as immunomodulators. Their compounds target specific immune cell subsets within the body to provide potential therapeutic benefits in various diseases. By leveraging their expertise in immunology and small molecule drug design, Rapt strives to deliver innovative treatment options to patients in need.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 32.877 mill.	$ - mill.	$ -129.865 mill.	41 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 32.877 mill.	$ - mill.	$ -129.865 mill.
Employees	Shares Outstanding	P/E
42	41 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

VCNX

$0.74

$-0.3400

-31.48%
Last 90 Days

VCNX

$0.74

$-0.3400

-31.48%

Vaccinex Inc

Vaccinex Inc shares went down -31.48% during the previous 90 days.

Vaccinex Inc operates on a biopharmaceutical business model, focusing on the development and commercialization of antibody-based therapies. The company utilizes its proprietary ActivMAb? Antibody Discovery Technology to discover and develop novel antibody therapeutics for the treatment of various diseases. Vaccinex collaborates with strategic partners and pharmaceutical companies to advance the clinical development and commercialization of its product candidates.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 1.553 mill.	$ -0.600 mill.	$ -18.634 mill.	2 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 1.553 mill.	$ -0.600 mill.	$ -18.634 mill.
Employees	Shares Outstanding	P/E
51	2 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

PRFX

$2.08

$-0.9400

-31.13%
Last 90 Days

PRFX

$2.08

$-0.9400

-31.13%

Painreform Ltd

Painreform Ltd stock declined -31.13% during the previous 90 days.

Painreform Ltd operates under a business model focused on developing and commercializing innovative pharmaceutical solutions for pain management. Their approach involves creating novel drug formulations and delivery systems to improve the efficacy, safety, and patient experience in treating acute and chronic pain.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 0.943 mill.	$ - mill.	$ -14.588 mill.	0 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 0.943 mill.	$ - mill.	$ -14.588 mill.
Employees	Shares Outstanding	P/E
-	0 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

PMN

$0.6275

$-0.2626

-29.50%
Last 90 Days

PMN

$0.6275

$-0.2626

-29.50%

Promis Neurosciences inc

Promis Neurosciences Inc stock went down -29.50% during the previous 90 days.

Promis Neurosciences Inc is a biotech company focused on developing innovative therapies for neurodegenerative diseases like Alzheimer*s and ALS. Their business model revolves around leveraging their expertise in neurosciences to discover and develop novel drug candidates that target protein misfolding, a key driver of these diseases. By translating their research into potential therapies, Promis Neurosciences aims to address unmet medical needs and improve the lives of patients suffering from neurodegenerative disorders.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 15.852 mill.	$ - mill.	$ 2.779 mill.	25 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 15.852 mill.	$ - mill.	$ 2.779 mill.
Employees	Shares Outstanding	P/E
18	25 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

OGN

$11.12

$-4.6200

-29.35%
Last 90 Days

OGN

$11.12

$-4.6200

-29.35%

Organon and Co

Organon And Co stock dropped -29.35% during the previous 90 days.

Organon and Co*s business model revolves around developing and manufacturing pharmaceutical products.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 2,885.189 mill.	$ 6,403.000 mill.	$ 864.000 mill.	259 mill.	3.35	Y/Y -0.38 %

Market Cap.	Revenues TTM	Net Income TTM
$ 2,885.189 mill.	$ 6,403.000 mill.	$ 864.000 mill.
Employees	Shares Outstanding	P/E
10,000	259 mill.	3.35
Revenue Growth	Income Growth
MRQ Y/Y -0.38 %	MRQ Y/Y -80.04 %

PMVP

$0.99

$-0.3800

-27.74%
Last 90 Days

PMVP

$0.99

$-0.3800

-27.74%

Pmv Pharmaceuticals Inc

Pmv Pharmaceuticals Inc stock dropped -27.74% during the previous 90 days.

Pmv Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing precision therapies for cancer patients. They employ a collaborative business model that combines deep scientific expertise, strategic partnerships, and advanced technology to identify and target specific genetic alterations in cancer cells. By leveraging these insights, Pmv Pharmaceuticals aims to create innovative treatments that can improve patient outcomes and address unmet medical needs in oncology.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 50.984 mill.	$ - mill.	$ -58.709 mill.	52 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 50.984 mill.	$ - mill.	$ -58.709 mill.
Employees	Shares Outstanding	P/E
47	52 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

YMAB

$4.505

$-1.6550

-26.87%
Last 90 Days

YMAB

$4.505

$-1.6550

-26.87%

Y mabs Therapeutics inc

Y Mabs Therapeutics Inc shares declined -26.87% during the previous 90 days.

Ymabs Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for the treatment of cancer.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 199.471 mill.	$ 87.684 mill.	$ -29.666 mill.	44 mill.	-	Y/Y 29.53 %

Market Cap.	Revenues TTM	Net Income TTM
$ 199.471 mill.	$ 87.684 mill.	$ -29.666 mill.
Employees	Shares Outstanding	P/E
100	44 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 29.53 %	MRQ Y/Y - %

ETST

$0.135

$-0.0470

-25.82%
Last 90 Days

ETST

$0.135

$-0.0470

-25.82%

Earth Science Tech Inc

Earth Science Tech Inc shares declined -25.82% during the previous 90 days.

Earth Science Tech Inc is a biotechnology company focused on developing and marketing innovative hemp cannabinoid-based products. Their business model revolves around research, development, manufacturing, and distribution of high-quality CBD and nutraceuticals for various industries, including the pharmaceutical and nutrition sectors.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 40.890 mill.	$ 30.870 mill.	$ 2.313 mill.	303 mill.	19.29	Y/Y 117.75 %

Market Cap.	Revenues TTM	Net Income TTM
$ 40.890 mill.	$ 30.870 mill.	$ 2.313 mill.
Employees	Shares Outstanding	P/E
-	303 mill.	19.29
Revenue Growth	Income Growth
MRQ Y/Y 117.75 %	MRQ Y/Y -8.44 %

OWPC

$0.0199

$-0.0067

-25.19%
Last 90 Days

OWPC

$0.0199

$-0.0067

-25.19%

One World Products Inc

One World Products Inc stock dropped -25.19% during the previous 90 days.

One World Products Inc*s business model focuses on selling a variety of products through various channels, possibly including online platforms, retail stores, or direct sales.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 2.261 mill.	$ 0.003 mill.	$ -5.895 mill.	114 mill.	-	Y/Y -74.31 %

Market Cap.	Revenues TTM	Net Income TTM
$ 2.261 mill.	$ 0.003 mill.	$ -5.895 mill.
Employees	Shares Outstanding	P/E
-	114 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -74.31 %	MRQ Y/Y - %

PBLA

$0.28

$-0.0910

-24.53%
Last 90 Days

PBLA

$0.28

$-0.0910

-24.53%

Panbela Therapeutics Inc

Panbela Therapeutics Inc stock declined -24.53% during the previous 90 days.

Panbela Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative and effective treatments for pancreatic cancer. They aim to leverage their expertise in drug development and strategic partnerships to bring novel therapies to the market and address the unmet medical needs of patients with this devastating disease.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 1.359 mill.	$ - mill.	$ -27.917 mill.	5 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 1.359 mill.	$ - mill.	$ -27.917 mill.
Employees	Shares Outstanding	P/E
26	5 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

PPBT

$2.6768

$-0.8632

-24.38%
Last 90 Days

PPBT

$2.6768

$-0.8632

-24.38%

Purple Biotech Ltd

Purple Biotech Ltd shares went down -24.38% during the previous 90 days.

Purple Biotech Ltd is a biopharmaceutical company that focuses on developing innovative therapeutic solutions for various diseases. They generate revenue by licensing out their technology and products, as well as through collaborations and partnerships with other industry players.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ - mill.	$ - mill.	$ 21.760 mill.	- mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ - mill.	$ - mill.	$ 21.760 mill.
Employees	Shares Outstanding	P/E
-	- mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y 17.83 %

PHVS

$13.99

$-4.3700

-23.80%
Last 90 Days

PHVS

$13.99

$-4.3700

-23.80%

Pharvaris N v

Pharvaris N V stock went down -23.80% during the previous 90 days.

Pharvaris N is a pharmaceutical company with a business model centered around developing and commercializing innovative therapies for rare diseases. They aim to address significant unmet medical needs by leveraging their expertise in drug discovery and development. Through strategic partnerships and collaborations, Pharvaris N seeks to bring life-changing treatments to patients worldwide.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 470.437 mill.	$ - mill.	$ -85.492 mill.	34 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 470.437 mill.	$ - mill.	$ -85.492 mill.
Employees	Shares Outstanding	P/E
-	34 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %